NASDAQ · NEUP
Neuphoria Therapeutics Inc.
$3.11+$0.05 (+1.52%)
Neuphoria Therapeutics Inc.’s quoted price sits in the lower half of its reported 52-week range, 43.82% below the high.
Loading market information…
NASDAQ · GMDA · USD
Stock price, earnings
Quote as of Jun 17, 2025, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Gamida Cell Ltd.’s quoted price sits in the lower half of its reported 52-week range, 17.22% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Gamida Cell Ltd.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Gamida Cell Ltd. operates as a clinical-stage biopharmaceutical firm, dedicated to pioneering cell therapies aimed at eradicating blood cancers and other severe hematological conditions. The company's leading investigational product, omidubicel—a specialized cell therapy—has successfully concluded its Phase III clinical evaluation for individuals afflicted with high-risk hematologic malignancies. Furthermore, it is currently undergoing Phase I/II trials for patients suffering from severe aplastic anemia. Another significant therapeutic candidate, GDA-201, an immunotherapy harnessing natural killer cells, is progressing through Phase I/II studies to address relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. Beyond these, Gamida Cell is actively advancing a broader natural killer (NK) cell pipeline, which includes GDA-301, GDA-401, GDA-501, and GDA-601, with the ambition of treating both hematologic cancers and solid tumors. Founded in 1998, the company maintains its corporate headquarters in Jerusalem, Israel.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 01:59 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| $0.00 |
| Q2 2022 | Aug 15, 2022 | -$0.310.0% vs estimate | $0.00 |
|---|
THE ANALYST VIEW
8 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$3.11+$0.05 (+1.52%)
Neuphoria Therapeutics Inc.’s quoted price sits in the lower half of its reported 52-week range, 43.82% below the high.
$5.20+$1.69 (+48.15%)
TNF Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 97.33% below the high.
$1.71+$1.71 (+100.0%)
Aptose Biosciences Inc.’s quoted price sits in the lower half of its reported 52-week range, 96.04% below the high.
$0.24+$0.01 (+5.66%)
Hillstream BioPharma, Inc.’s quoted price sits in the lower half of its reported 52-week range, 91.06% below the high.
$0.03-$0.02 (-31.78%)
Gritstone bio, Inc.’s quoted price sits in the lower half of its reported 52-week range, 98.98% below the high.
$0.09-$0.00 (-1.32%)
Atreca, Inc.’s quoted price sits in the lower half of its reported 52-week range, 92.5% below the high.
$0.00$0.00 (0.0%)
RVL Pharmaceuticals plc’s quoted price sits in the lower half of its reported 52-week range, 98.0% below the high.
$0.30+$0.30 (+100.0%)
Altamira Therapeutics Ltd.’s quoted price sits in the lower half of its reported 52-week range, 27.85% below the high.
